कृपया अन्य खोज का प्रयास करें
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer. Further, the company develops APL-1401 to treat moderately to severely active ulcerative colitis; and ASN-1733 to treat acinetobacter baumannii infection. Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Hanzhong Li | - | - | Member of Clinical Advisory Committee |
Zhisong He | - | - | Member of Clinical Advisory Committee |
Dingwei Ye | - | - | Chairman of Clinical Advisory Committee |
Fangjian Zhou | - | - | Member of Clinical Advisory Committee |
Bin Huang | 57 | 2020 | Independent Director |
Joseph Liao | - | 2024 | Member of the Advisory Board |
Xianxian Li | 35 | 2020 | Supervisor |
Zeng Liu | 40 | 2020 | Director |
Chengfeng Zhuang | 61 | 2019 | Deputy GM & Director |
Zhihua Yu | 57 | 2017 | Director |
Badrinath Konety | - | 2022 | Member of Scientific Advisory Board |
Yinglu Guo | - | - | Honorary Chairman of Clinical Advisory Committee |
Bing Hui Zhang | 61 | 2020 | Independent Director |
Kan Chen | 42 | 2020 | Director |
Yi Zhong | 51 | 2020 | Chairman of the Supervisory Board |
Yangwen Qin | 56 | 2020 | Independent Director |
Mingyuan Yang | 41 | 2020 | Financial , Director & Board Secretary |
Neal D. Shore | - | 2024 | Member of the Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है